- Trial phase
- Approved
- Time to market
- Already approved and commercially marketed since 2012 (first approval for medullary thyroid cancer)
- Why 4/10
- Cabozantinib is already approved and marketed with no pending FDA decision for the drug itself. The next major binary catalyst for Exelixis is the zanzalintinib PDUFA on December 3, 2026, a separate drug. Without a pending regulatory decision for cabozantinib, the impact score is capped at 4 (commercial cash cow, no imminent binary).
Cabozantinib is Exelixis's sole approved drug, generating ~$2.12B in 2025 U.S. net revenue (17% YoY growth). The stock's next catalyst is the zanzalintinib PDUFA (Dec 3, 2026), not cabozantinib. For Kura Oncology holders: Kura's darlifarnib+cabozantinib combo data (44% ORR in pretreated ccRCC) is about Kura's drug resensitizing tumors to cabozantinib, not about cabozantinib itself. Watch Exelixis for cabozantinib commercial trends and the zanzalintinib readout.
Price Chart
Executive Summary
Cabozantinib (brand names Cabometyx and Cometriq) is an already-approved, commercially successful tyrosine kinase inhibitor discovered and developed by Exelixis (EXEL). It generated ~$2.12B in U.S. net product revenue in 2025 and $2.9B globally including partner sales. With five FDA-approved indications across medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors, it is Exelixis's sole marketed drug and the economic engine of the company. The filing hint pointed to Kura Oncology, Kura is studying cabozantinib in combination with their own pipeline drug darlifarnib (KO-2806) in the FIT-001 trial for kidney cancer, but does not own or develop cabozantinib. With no pending regulatory decision for cabozantinib itself, the stock's next binary catalyst is zanzalintinib's PDUFA on December 3, 2026.
How It Works
Cabozantinib is a small-molecule pill that blocks multiple signaling pathways cancers use to grow and spread, it inhibits 'tyrosine kinases' including VEGFR2 (which tumors hijack to grow blood vessels), c-MET, and AXL (which drive cancer cell growth and spread). By hitting several targets at once, it cuts off the tumor's blood supply and directly slows cancer cell growth.
Trial Status
Cabozantinib is FDA-approved for 5 indications: medullary thyroid cancer (2012, Cometriq capsules), advanced renal cell carcinoma (2016, Cabometyx tablets), hepatocellular carcinoma (2019), differentiated thyroid cancer (2021), and pancreatic/extra-pancreatic neuroendocrine tumors (March 2025). Ongoing investigator-sponsored trials continue to explore additional combinations.
The Two-Sided Case
Upcoming Catalysts
- No pending FDA decision for cabozantinib itself. For Exelixis as a whole: zanzalintinib PDUFA date of December 3, 2026. For Kura Oncology's combination study: ongoing Phase 1b FIT-001 dose-optimization portion enrollment; KCRS presentation of long-term follow-up data on July 24, 2026.
- Exelixis Q2 2026 earnings (expected late July/early August 2026) for cabozantinib sales trends.
- Ongoing label expansion/clinical trial data presentations at medical meetings (ASCO 2026 presentations in progress).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Kura Oncology, Inc. Press Release KURA ·Originating report